Sphingosine-1-phosphate (S1P) is the bioactive lipid that is one of the most important regulators of the immune cell circulation — it is produced by the sphingosine kinase (SPHK1 and SPHK2) enzymes in the erythrocytes, the endothelial cells, and the immune cells, and it is the ligand of the S1P receptors (S1PR1 through S1PR5) on the lymphocytes, the dendritic cells, and the endothelial cells. The S1P-S1PR1 signalling is the primary mechanism by which the lymphocytes exit the lymph nodes and enter the systemic circulation — the S1P gradient (high in the lymph, low in the tissues) guides the lymphocytes out of the tissues and into the lymphatic vessels, and the S1PR1 on the lymphocytes is the receptor that senses this gradient and directs the lymphocyte trafficking. The fingolimod (FTY720) is a structural analogue of the sphingosine that is used for the treatment of the multiple sclerosis — it is phosphorylated in the body to become the fingolimod-phosphate, which binds to the S1PR1 and internalises it, thereby preventing the lymphocytes from exiting the lymph nodes and reducing the autoimmune attack on the CNS. Without adequate sphingosine-1-phosphate and S1PR1 signalling, the lymphocyte trafficking is dysregulated, the immune function is impaired, and the autoimmunity develops — the hallmark of the sphingosine-1-phosphate deficiency and of the S1P signalling disorders that are associated with the multiple sclerosis, the rheumatoid arthritis, and the inflammatory bowel disease.
S1P and the Multiple Sclerosis
S1P supports the treatment of the multiple sclerosis primarily through the modulation of the lymphocyte trafficking and the reduction of the autoimmune attack on the CNS — the fingolimod, the siponimod, and the ozanimod are all S1P receptor modulators that are approved for the treatment of the multiple sclerosis, and they work by trapping the lymphocytes in the lymph nodes, thereby preventing them from infiltrating the CNS and causing the demyelination. The S1P also has direct effects on the oligodendrocytes and the neurons — the S1PR5 on the oligodendrocytes is involved in the oligodendrocyte differentiation and myelination, and the S1PR1 on the neurons is involved in the neuroprotection and the axon regeneration. The combination of the lymphocyte trafficking modulation and the direct neuroprotective effects makes the S1P pathway one of the most important and most effective therapeutic targets for the multiple sclerosis — and it explains why the S1P receptor modulators are among the most widely used and most effective disease-modifying therapies for the relapsing-remitting multiple sclerosis.
The clinical importance of the S1P pathway for the multiple sclerosis treatment is underscored by the FREEDOMS and the TRANSFORMS trials — the FREEDOMS trial found that the fingolimod at 0.5mg daily significantly reduced the annual relapse rate (by 54%) and the disability progression (by 30%) compared to the placebo in people with the relapsing-remitting multiple sclerosis, and the TRANSFORMS trial found that the fingolimod was superior to the interferon beta-1a for the reduction of the relapse rate (by 52%) and for the MRI lesion burden — making the S1P receptor modulation one of the most effective and most important advances in the multiple sclerosis therapy in decades.
Practical Application
For general S1P support for the immune regulation and for the multiple sclerosis management, the evidence-based approach is to support the endogenous S1P synthesis through the provision of the adequate sphingosine and through the activation of the sphingosine kinase enzymes. The S1P synthesis is dependent on the sphingosine availability (which is derived from the ceramide breakdown) and on the sphingosine kinase activity (which is regulated by the inflammatory cytokines, the growth factors, and the immune signals). The best nutritional approach to support the S1P synthesis is to supplement with the omega-3 fatty acids (which support the membrane phospholipid composition and which work synergistically with the S1P for the immune cell function), with the vitamin D (which regulates the sphingosine kinase activity and which works synergistically with the S1P for the immune modulation and for the prevention of the autoimmunity). For comprehensive S1P support and multiple sclerosis management, the S1P pathway approach pairs well with the omega-3 fatty acids (which are the primary structural components of the neuronal membrane and which have complementary anti-inflammatory effects on the CNS — the combination of the omega-3 fatty acids and the S1P modulation is one of the most effective approaches for the management of the multiple sclerosis and for the protection of the myelin sheath), with the vitamin D (which is a regulator of the immune function and which works synergistically with the S1P for the modulation of the lymphocyte trafficking and for the prevention of the autoimmunity — the combination of the vitamin D and the S1P pathway support is one of the most effective approaches for the prevention and the treatment of the multiple sclerosis), with the alpha-lipoic acid (which is a potent antioxidant that protects the oligodendrocytes from the oxidative damage and which works synergistically with the S1P for the myelin protection and for the oligodendrocyte survival — the combination of the alpha-lipoic acid and the S1P pathway support is one of the most effective combinations for the prevention of the demyelination and for the promotion of the remyelination in the multiple sclerosis), and with the biotin (which is a cofactor for the carboxylases and which has been shown to improve the clinical outcomes in people with the progressive multiple sclerosis — the high-dose biotin supplementation at 300mg daily is one of the most promising experimental therapies for the primary progressive and secondary progressive multiple sclerosis, and it works synergistically with the S1P pathway support for the promotion of the remyelination and for the improvement of the neurological function).
Leave a Reply